Results 1 to 10 of about 109,604 (273)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Pharmaceuticals, 2021
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit ...
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Giuseppe Curigliano   +5 more
doaj   +1 more source

Proliferative diabetic retinopathy transcriptomes reveal angiogenesis, anti-angiogenic therapy escape mechanisms, fibrosis and lymphatic involvement

Scientific Reports, 2021
Proliferative diabetic retinopathy (PDR) is a sight-threatening diabetic complication in urgent need of new therapies. In this study we identify potential molecular mechanisms and target candidates in the pathogenesis of PDR fibrovascular tissue ...
Ani Korhonen, Erika Gucciardo, Kaisa Lehti, Sirpa Loukovaara   +3 more
doaj   +1 more source

Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice

Biomolecules, 2022
Passive immunotherapy is a very promising approach for the treatment of Alzheimer’s disease (AD). Among the different antibodies under development, those targeting post-translationally modified Aβ peptides might combine efficient reduction in beta ...
Kathrin Gnoth, Stefanie Geissler, Julia Feldhaus, Nadine Taudte, Victoria Ilse, Sebastian Zürner, Sebastian Greiser, Ulf-Dietrich Braumann, Jens-Ulrich Rahfeld, Holger Cynis, Stephan Schilling   +10 more
doaj   +1 more source

Antibody–drug conjugates in solid tumors: a look into novel targets

Journal of Hematology & Oncology, 2021
Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy.
Carmen Criscitiello, Stefania Morganti, Giuseppe Curigliano   +2 more
doaj   +1 more source

Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology

Alzheimer’s Research & Therapy, 2020
Background Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far.
Kathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, Sandra Konrath, Mathias Schenk, Nadine Taudte, Daniel Ramsbeck, Vera Rieckmann, Stefanie Geissler, Rico Eichentopf, Susan Barendrecht, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner, Holger Cynis, Jens-Ulrich Rahfeld, Stephan Schilling   +16 more
doaj   +1 more source

A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice

Alzheimer’s Research & Therapy, 2023
Background Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain.
Susan Barendrecht, An Schreurs, Stefanie Geissler, Victor Sabanov, Victoria Ilse, Vera Rieckmann, Rico Eichentopf, Anja Künemund, Benjamin Hietel, Sebastian Wussow, Katrin Hoffmann, Kerstin Körber-Ferl, Ravi Pandey, Gregory W. Carter, Hans-Ulrich Demuth, Max Holzer, Steffen Roßner, Stephan Schilling, Christoph Preuss, Detlef Balschun, Holger Cynis   +20 more
doaj   +1 more source

Synthesis and structure–activity relationships of pyrazole-based inhibitors of meprin α and β

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Targeting metalloproteinases has been in the focus of drug design for a long time. However, meprin α and β emerged as potential drug targets just recently and are linked to several diseases with different pathological background.
Kathrin Tan, Christian Jäger, Stefanie Geissler, Dagmar Schlenzig, Mirko Buchholz, Daniel Ramsbeck   +5 more
doaj   +1 more source

Perillaldehyde improves cognitive function in vivo and in vitro by inhibiting neuronal damage via blocking TRPM2/NMDAR pathway

Chinese Medicine, 2021
Background Vascular cognitive dysfunction in patients with vascular dementia (VD) is a kind of severe cognitive dysfunction syndrome caused by cerebrovascular diseases.
Yue Qiu, Xian-jun Xue, Geng Liu, Miao-miao Shen, Chun-yan Chao, Jie Zhang, Ya-qi Guo, Qian-qian Niu, Ya-nan Yu, Yu-ting Song, Huan-huan Wang, Shuang-xi Wang, Yu-jing Chen, Lin-hua Jiang, Peng Li, Ya-ling Yin   +15 more
doaj   +1 more source

Puerarin Alleviates Vascular Cognitive Impairment in Vascular Dementia Rats

Frontiers in Behavioral Neuroscience, 2021
Cerebral ischemia triggers vascular dementia (VD), which is characterized by memory loss, cognitive deficits, and vascular injury in the brain. Puerarin (Pur) represents the major isoflavone glycoside of Radix Puerariae, with verified neuroprotective ...
Tiantian Zhu, Tiantian Zhu, Tiantian Zhu, Moli Zhu, Moli Zhu, Moli Zhu, Yue Qiu, Yue Qiu, Yue Qiu, Zeqing Wu, Zeqing Wu, Zeqing Wu, Ning Huang, Ning Huang, Ning Huang, Guangrui Wan, Guangrui Wan, Guangrui Wan, Jian Xu, Jian Xu, Jian Xu, Ping Song, Ping Song, Ping Song, Shuangxi Wang, Shuangxi Wang, Shuangxi Wang, Yaling Yin, Yaling Yin, Yaling Yin, Peng Li, Peng Li, Peng Li   +32 more
doaj   +1 more source

Drug therapies in dermatology [PDF]

Clinical Medicine, 2014
This article explores the current and emerging therapies for skin disease, with a particular focus on chronic plaque psoriasis and metastatic malignant melanoma. We discuss the current biological therapies used for psoriasis and those on the horizon, including small molecules and biosimilars.
Aslam, Arif, Griffiths, Christopher E M
openaire   +4 more sources